DOAC in Unusual Site Venous Thrombosis (DUST)

University of Malta

Status: Completed

Conditions: Renal Vein Thrombosis; Retinal Vein Thrombosis; Ovarian Vein Thrombosis; Cerebral Vein Thrombosis; Splanchnic Vein Thrombosis

Treatments: Drug: Direct Oral Anticoagulants

Study type: Observational

Funder types: Other

Identifiers

NCT03778502

DUST

Details and patient eligibility

About

Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts outside the veins of the lower extremities and the pulmonary arteries, and includes splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis, ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban, edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing. Through an international multicentre prospective registry, the investigators aim to evaluate the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the safety and effectiveness of this approach in real life clinical practice.

Enrollment: 358 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs and pulmonary arteries
• Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)

Exclusion criteria

• Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site VTE